Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douwe Postmus

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 16, 2015
Continuous-Time Semi-Markov Models in Health Economic Decision Making: An Illustrative Example in Heart Failure Disease ManagementQi Cao, Erik Buskens, Talitha Feenstra, et al.
Nature Reviews. Clinical Oncology|December 7, 2021
The value of anticancer drugs - a regulatory viewFrancesco Pignatti, Ulla Wilking, Douwe Postmus, et al.
Clinical Pharmacology and Therapeutics|May 13, 2025
Expedited Approval in Oncology: A Study of European Regulators' Perspectives and Trade-OffsFrancesco Pignatti, Filip Josephson, Pierre Demolis, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 12, 2013
A multi-criteria decision analysis perspective on the health economic evaluation of medical interventionsDouwe Postmus, Tommi Tervonen, Gert van Valkenhoef, et al.
International Journal of Radiation Oncology, Biology, Physics|June 7, 2011
Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancerJoachim Widder, Douwe Postmus, Jan F Ubbels, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 31, 2018
Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical explorationQi Cao, Erik Buskens, Hans L Hillege, et al.
Statistics in Medicine|July 19, 2012
A method for the early health technology assessment of novel biomarker measurement in primary prevention programsDouwe Postmus, Gimon de Graaf, Hans L Hillege, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2023
Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer settingDouwe Postmus, Saskia Litiere, Jan Bogaerts, et al.
Journal of Clinical Epidemiology|December 27, 2011
Multicriteria benefit-risk assessment using network meta-analysisGert van Valkenhoef, Tommi Tervonen, Jing Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2025
Beyond traditional endpoints: A multi-state modelling approach to integrating morbidity and mortality in cancer treatments evaluationDouwe Postmus, Jan J Cornelissen, Jan Bogaerts, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 16, 2015
Continuous-Time Semi-Markov Models in Health Economic Decision Making: An Illustrative Example in Heart Failure Disease ManagementQi Cao, Erik Buskens, Talitha Feenstra, et al.
Nature Reviews. Clinical Oncology|December 7, 2021
The value of anticancer drugs - a regulatory viewFrancesco Pignatti, Ulla Wilking, Douwe Postmus, et al.
Clinical Pharmacology and Therapeutics|May 13, 2025
Expedited Approval in Oncology: A Study of European Regulators' Perspectives and Trade-OffsFrancesco Pignatti, Filip Josephson, Pierre Demolis, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 12, 2013
A multi-criteria decision analysis perspective on the health economic evaluation of medical interventionsDouwe Postmus, Tommi Tervonen, Gert van Valkenhoef, et al.
International Journal of Radiation Oncology, Biology, Physics|June 7, 2011
Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancerJoachim Widder, Douwe Postmus, Jan F Ubbels, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 31, 2018
Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical explorationQi Cao, Erik Buskens, Hans L Hillege, et al.
Statistics in Medicine|July 19, 2012
A method for the early health technology assessment of novel biomarker measurement in primary prevention programsDouwe Postmus, Gimon de Graaf, Hans L Hillege, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2023
Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer settingDouwe Postmus, Saskia Litiere, Jan Bogaerts, et al.
Journal of Clinical Epidemiology|December 27, 2011
Multicriteria benefit-risk assessment using network meta-analysisGert van Valkenhoef, Tommi Tervonen, Jing Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2025
Beyond traditional endpoints: A multi-state modelling approach to integrating morbidity and mortality in cancer treatments evaluationDouwe Postmus, Jan J Cornelissen, Jan Bogaerts, et al.
Pageof 8